Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thomas Rothe1

  • 1Spital Davos, Pneumologie, Davos.

Therapeutische Umschau. Revue Therapeutique
|November 26, 2019
PubMed
Summary
This summary is machine-generated.

Inhaled corticosteroids (ICS) are standard for asthma but debated for COPD due to side effects. However, ICS are crucial for patients with asthma-COPD overlap.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Remission in Patients with Severe Eosinophilic Asthma - A Single-Arm Observational Study with Benralizumab.

Journal of asthma and allergy·2026
Same author

Periodic intrafraction image-guided focal dose-escalated stereotactic body radiotherapy for prostate carcinoma on a standard linear accelerator.

Physics and imaging in radiation oncology·2026
Same author

Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2025
Same author

The Effect of Comorbidities on Asthma-Related Outcomes Over a Two-Year Period: A Prospective Analysis of Swiss Severe Asthma Registry (SSAR).

Journal of asthma and allergy·2025
Same author

[Asthma essentials for the practitioner].

Praxis·2025
Same author

Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study.

Journal of asthma and allergy·2024
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Inhaled corticosteroids (ICS) are a cornerstone therapy for asthma management.
  • Current COPD treatment trends have shifted towards dual bronchodilator therapy (LABA/LAMA), moving away from ICS.
  • Emerging research prompts a re-evaluation of ICS use in Chronic Obstructive Pulmonary Disease (COPD).

Purpose of the Study:

  • To evaluate the current evidence regarding the use of inhaled corticosteroids (ICS) in asthma and COPD.
  • To discuss the risks and benefits of ICS therapy in the context of COPD.
  • To identify patient subgroups within COPD who may benefit from ICS treatment.

Main Methods:

  • Review of current clinical guidelines and recent scientific literature.

Related Experiment Videos

  • Analysis of data concerning the efficacy and safety of ICS in asthma and COPD.
  • Consideration of treatment outcomes and adverse events associated with ICS.

    • Main Results:

    • ICS therapy is well-established and effective for asthma.
    • ICS use in COPD has declined, with a preference for LABA/LAMA dual therapy.
    • ICS therapy in COPD is associated with increased risks of pneumonia and osteoporosis.
    • Patients with asthma-COPD overlap (ACO) demonstrably benefit from ICS therapy.

    Conclusions:

    • While ICS are not recommended for all COPD patients due to potential side effects, they are essential for those with asthma-COPD overlap.
    • The decision to use ICS in COPD requires careful patient selection and risk-benefit assessment.
    • Further research may clarify the role of ICS in specific COPD phenotypes.